A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

Exclusion Criteria

• •Part A and Part B: Individuals in Part A and Part B who meet any of the following criteria will be excluded from participation in this study:
• •1. Diagnosis of any form of CAH other than classic 21-OHD.
• •2. Participants treated with other GCs within 30 days of Screening.
• •3. Stress dose of GC therapy within 2 weeks of start of Screening, defined as any dose above the normal maintenance dose, including but not limited to intravenous (IV) or intramuscular (IM) hydrocortisone.
• •4. Use of growth hormones within 1 week of start of Screening for short acting, or within 6 weeks of start of Screening for long acting.
• •5. Use of a corticotropin-releasing factor receptor antagonist within 14 days of Screening.
• •6. History of cancer excluding cured/treated dermal squamous or basal cell carcinoma or cervical carcinoma in situ.
• •7. Abnormal sleep/wake cycles (as determined by the Investigator).
• •8. Female participants who are pregnant or lactating.
• •9. Participants who have been dosed with an investigational drug (including atumelnant) in any prior clinical study within 60 days or 5 half-lives (whichever is longer) prior to the first dose.